450 East 29th Street
9 articles with Kadmon
Kadmon Holdings, Inc. announced that it will voluntarily transfer its stock exchange listing from the New York Stock Exchange to the Nasdaq Global Select Market.
Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease
Application Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program
Kadmon Holdings, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to belumosudil, the Company's Rho-associated coiled-coil kinase 2 inhibitor, for the treatment of systemic sclerosis.
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following virtual investor conferences: H.C. Wainwright 22 nd Annual Global Investment Conference Date: Monday, September 14, 2020 Time: 11:00 a.m. ET
Kadmon Holdings, Inc. (NYSE:KDMN) today announced the appointment of Nancy Miller-Rich to its Board of Directors. Nancy possesses an extensive, decades-long track record of business development and commercialization success in varying roles across globally focused healthcare organizations said Harlan W. Waksal, M.D., President and CEO of Kadmon.
Kadmon Holdings, Inc. provided a business update and reported financial and operational results for the second quarter of 2020.
Kadmon Holdings, Inc. announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Raymond James 2020 Virtual Human Health Innovation Conference on Thursday, June 18, 2020 at 1:00 p.m. ET.
Kadmon Holdings, Inc. provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2019..
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.